Fosun Pharmaceutical Group published the Q1~3 Report on Oct. 29th, which shows, Fosun Pharmaceutical Group achieved net profit 2.217 billion RMB during the reporting periods, with YoY increases 264%, and net profit for per share achieved 1.79 RMB. The increase of company operating net profit was mainly generated from continuous increase of the drug R&D and manufacturing and pharmaceutical commercial business, on the other hand, the successful listing of Sinopharm Group obviously increased the company revenue.

On Sep.23rd, Sinopharm Group, which was shared by Fosun Pharmaceutical Group, listed on the main board of Hong Kong stock exchange with issue price was 16 HK$/share. Before exercising of the over-allotment option, Sinopharm Group collected capital net amount achieves approximately 8.408 billion HK$. The corresponding equity to the stock ownership of Sinopharm Group hold by Fosun Pharmaceutical Group was increased, and was summed in the current gains and losses of the company, which contributes 1.732 billion RMB to net profit, and 1.40 RMB to per share. After Sinopharm Group listing on Hong Kong, the market value of Sinopharm Group hits 63.2 billion HK$, equivalent to 55.7 billion RMB by calculating on the basis of closing price 27.9 HK$/share of Oct. 28th. It is not only the largest pharmaceutical listed company in China, but also ranks the top three of market value in global listed pharmaceutical distribution companies.

During the reporting periods, main business of Fosun Pharma maintains solid growth, the revenue of Q1~3 increased 9% YoY. The report shows that, the recurring income increased 25%, which comes from the rapid growth of drug R&D, manufacturing and distribution.